## Clinical Context This patient presents with imaging and clinical features consistent with a **low-grade glioma (WHO Grade II)**: - Small size (2.5 cm) with well-demarcated margins - T2/FLAIR hyperintensity without contrast enhancement (intact blood–brain barrier, low cellularity) - Minimal perilesional edema, no mass effect - Neurologically stable — no seizures, no focal deficits - Indolent 6-month course ## Management Strategy for Low-Grade Gliomas **Key Point:** For a neurologically stable patient with a suspected low-grade glioma and no seizures or focal deficits, the standard initial approach is **serial MRI surveillance with neurosurgical consultation**, not immediate resection, upfront radiotherapy, or reflexive biopsy. ### Why Option B is Correct 1. **Serial MRI every 3–6 months** establishes growth kinetics. A lesion that remains stable over 12–24 months carries a very different prognosis from one that doubles in volume within 6 months. 2. **Neurosurgical consultation** at baseline is essential — it does not commit the patient to surgery but ensures a specialist is tracking the case and can intervene promptly if progression occurs (>25% volume increase, new enhancement, new symptoms). 3. **Deferred resection** in asymptomatic patients is supported by multiple prospective series; upfront surgery in this setting has not been shown to improve overall survival and carries operative morbidity (Harrison's Principles of Internal Medicine, 21e, Ch. 375). ### Why the Other Options Are Incorrect - **Option A (Immediate resection regardless of symptoms):** Aggressive upfront surgery is not indicated for a small, asymptomatic, non-enhancing lesion. Surgical morbidity in the temporal lobe (language, memory) must be weighed against benefit. - **Option C (Immediate radiotherapy):** Upfront RT is not standard for asymptomatic low-grade glioma; it is reserved for high-risk features (age >40, large size, eloquent location, IDH-wildtype, or post-operative residual disease). Early RT increases neurocognitive toxicity without survival benefit in low-risk patients (EORTC 22845). - **Option D (Stereotactic biopsy first):** While molecular profiling (IDH mutation, 1p/19q co-deletion, MGMT methylation) is invaluable for prognosis and treatment planning, a stereotactic biopsy is an invasive procedure with a ~1–2% risk of hemorrhage or neurological deficit. In a neurologically stable patient with a classic imaging appearance, the standard of care is to initiate surveillance and plan tissue diagnosis at the time of surgical resection *if and when* the lesion progresses or becomes symptomatic — not as an immediate first step. Biopsy-first is more appropriate when the diagnosis is uncertain (e.g., atypical imaging, possible lymphoma, metastasis) or when the patient is not a surgical candidate but treatment decisions hinge on molecular data. **Clinical Pearl:** Low-grade gliomas have a median natural history of 5–10 years before malignant transformation. The 2021 WHO CNS classification emphasizes molecular markers (IDH, 1p/19q), but obtaining these markers does not require an immediate invasive procedure in a stable patient — they are typically obtained at the time of planned resection. ## Evidence-Based Algorithm **High-Yield:** Low-grade glioma management: ``` Suspected LGG on MRI ↓ Neurologically stable? No seizures/deficits? ↓ YES Serial MRI (3–6 monthly) + Neurosurgical consultation ↓ Progression (volume ↑, new enhancement, new symptoms)? YES → Resection ± adjuvant therapy (RT/TMZ based on molecular profile) NO → Continue surveillance ``` **Mnemonic — SLOW:** - **S**urveillance with serial MRI - **L**ow immediate malignant transformation risk - **O**bservation preferred over upfront intervention - **W**ait for progression before resection/biopsy [cite: Harrison 21e Ch 375; Robbins & Kumar Basic Pathology 10e Ch 28; EORTC 22845 trial]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.